Lidocaine (hydrochloride)
CAT:
804-HY-B0185A-01
Size:
500 mg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Lidocaine (hydrochloride)
UNSPSC Description:
Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].Target Antigen:
Apoptosis; ERK; MEK; NF-κB; Sodium ChannelType:
Reference compoundRelated Pathways:
Apoptosis;MAPK/ERK Pathway;Membrane Transporter/Ion Channel;NF-κB;Stem Cell/WntApplications:
Cancer-Kinase/proteaseField of Research:
Cancer; Cardiovascular DiseaseAssay Protocol:
https://www.medchemexpress.com/Lidocaine-hydrochloride.htmlPurity:
99.96Solubility:
DMSO : ≥ 100 mg/mL|H2O : ≥ 100 mg/mLSmiles:
O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.[H]ClMolecular Weight:
270.80References & Citations:
[1]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11.|[2]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233.|[3]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6.Eur Spine J. 2022 Sep 24.|J Phys D Appl Phys. 2019 Aug; 52(46).|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Dig Dis Sci. 2021 Jan 12.|Drug Des Devel Ther. 2024 Apr 9:18:1103-1114.|Int Immunopharmacol. 2023 Jan 11;115:109706.|J Neuroinflammation. 2017 Nov 2;14(1):211.|Mol Med Rep. 2022 May;25(5):150.|Nat Methods. 2021 Jul;18(7):788-798.|Neurogastroenterol Motil. 2023 Sep 21;e14677.|PLoS Pathog. 2023 Feb 3;19(2):e1011126.|Stem Cell Res Ther. 2021 Feb 4;12(1):107.|University of Glasgow. School of Cancer Sciences.Shipping Conditions:
Room TemperatureStorage Conditions:
4°C (Powder, sealed storage, away from moisture and light)Clinical Information:
LaunchedCAS Number:
73-78-9